Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial.

9–12 However, the benefit of SITT versus ICS/LABA for other clinical outcomes vary: CAPTAIN showed no significant reduction in moderate/severe exacerbation rates and nominally significant improvements in symptom control; 10 IRIDIUM showed no significant reduction in exacerbations or symptom control; 9 TRIMARAN/TRIGGER demonstrated significant reductions in moderate/severe exacerbations in TRIMARAN but not TRIGGER; 11 and KALOS/LOGOS showed varying improvements in severe exacerbation

also in 7,732 other papers